Policy | November 11, 2025
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Investment to expand manufacturing and global medicine supply capacity
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Subscribe To Our Newsletter & Stay Updated
